The total population examined within the study period was from March 2006 to August 2009.
In the total population examined, the prevalence of Selleck R788 PE was 2.2% [11]. In addition to the 76 HIV-positive cases included in the study, there were three HIV-positive women who developed PE (3.9%) and who were excluded from the study because this number was too small to allow valid comparisons of the prevalence of PE to be made between HIV-positive and HIV-negative women. None of the selected controls developed PE and all pregnancies resulted in the live birth of phenotypically normal neonates. In normal pregnancy the measured UtA-PI is affected by fetal crown–rump length, maternal age, body mass index, racial group and parity. In comparing normal with pathological pregnancies, the values of UtA-PI are expressed as multiples of the median (MoM) of the normal after appropriate adjustment for the above variables [11]. Normality of the data distribution was examined with the Kolmogorov–Smirnov test and probability plots. Data were expressed as mean ± standard deviation or as median and interquartile range (IQR) for normally and non-normally distributed data, respectively. Comparisons between groups were performed using the t-test or Mann–Whitney U-test for numerical data and the χ2 test for categorical data. Univariate regression analyses were performed where appropriate.
Power analysis indicated
that a sample of 76 HIV-positive and 2280 HIV-negative women would have more than 80% power (α 0.05) for Ruxolitinib clinical trial the detection of a mean difference of 0.26 in the mean UtA-PI (MoM) between the groups. As there are no previous data in pregnant women with HIV infection, the effect size was estimated from data presented in previous publications for pregnant women with known increased resistance in the uterine arteries, such as those who eventually develop PE [11]. The statistical analyses were performed using the Statistical Package for Social Sciences (Version 12.0; Carbohydrate SPSS, Chicago, IL, USA). The demographic and pregnancy characteristics and outcomes for the 76 HIV-positive and 2280 HIV-negative women are given in Table 1. In the HIV-positive group, 33 women (43.4%) were on antiretroviral treatment, including 14 (42.4%) on nucleoside reverse transcriptase inhibitors (NRTIs) and a protease inhibitor, 18 (54.5%) on NRTIs and a nonnucleoside reverse transcriptase inhibitor (NNRTI) and one (3.1%) on monotherapy. The median duration of treatment prior to the first trimester ultrasound scan was 22 months (IQR 7.5–39.5 months) and the majority of the women (n=29) were on antiretroviral treatment at the time of conception. Compared with the HIV-negative women, the HIV-positive women were more likely to be heavier, to be of African racial origin, to be nonsmokers and to deliver earlier and have smaller neonates.